Literature DB >> 7650167

High specificity of Trypanosoma cruzi epimastigote ribonucleoprotein as antigen in serodiagnosis of Chagas' disease.

M E Solana1, A M Katzin, E S Umezawa, C S Miatello.   

Abstract

We assessed the performance of an enzyme-linked immunosorbent assay (ELISA) with the Trypanosoma cruzi epimastigote ribosomal fraction (Tulahuen and Y strains) in order to improve the diagnostic specificity of the test. A total of 100 serum samples from patients with chronic Chagas' disease from Brazil and Argentina were studied. Sera from 116 patients, without Chagas' disease, including 10 with active mucocutaneous leishmaniasis and 20 with visceral leishmaniasis, were used as controls. Immunoglobulin G (IgG) antibodies against the ribosomal fraction (ribonucleoproteins [RNPs]) in the ELISA were found in 97% of samples from patients with Chagas' disease. A total of 99% of the sera from patients without the disease were negative, including sera from patients with mucocutaneous and visceral leishmaniases. The distribution of IgG isotypes in randomly chosen serum samples was determined by ELISA; IgG1 and IgG3 were predominant (100% exhibited IgG1 and 85% exhibited IgG3, and 50% also presented the IgG2 isotype. The distribution of the IgG subclasses was confirmed by the Western blot (immunoblot) technique. When total IgG was assayed by Western blot assay, no correlation was found between the pattern of serum reactivity and the clinical features of the patients with Chagas' disease. Therefore, no typical profile of polypeptide recognition could be associated with any clinical form of Chagas' disease (cardiomyopathy or megaviscera). Our results showed that sera from patients with Chagas' disease react with ribosomal antigens and display a typical profile of IgG isotypes (IgG1 plus IgG3). The RNP ELISA seems to have improved specificity compared with those of routine techniques such as the indirect immunofluorescence assay and hemagglutination because it better discriminates between patients with Chagas' disease and patients without the disease. Since sera from patients with leishmaniasis failed to show cross-reactivity with this antigen, the ELISA seems useful for detecting Chagas' disease as well as confirming the nature of sera, when it is doubtful whether the patients has Chagas' disease, by the isotype distribution of IgG.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650167      PMCID: PMC228195          DOI: 10.1128/jcm.33.6.1456-1460.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  GROWTH AND DIFFERENTIATION IN TRYPANOSOMA CRUZI. I. ORIGIN OF METACYCLIC TRYPANOSOMES IN LIQUID MEDIA.

Authors:  E P CAMARGO
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1964 May-Jun       Impact factor: 1.846

2.  Natural immunities.

Authors:  P Druilhe; H Bouharoun-Tayoun
Journal:  Res Immunol       Date:  1991-10

3.  Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease.

Authors:  M J Levin; E Mesri; R Benarous; G Levitus; A Schijman; P Levy-Yeyati; P A Chiale; A M Ruiz; A Kahn; M B Rosenbaum
Journal:  Am J Trop Med Hyg       Date:  1989-11       Impact factor: 2.345

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Autoantibodies in Chagas' disease. An antibody cross-reactive with human and Trypanosoma cruzi ribosomal proteins.

Authors:  E Bonfa; V S Viana; A C Barreto; N H Yoshinari; W Cossermelli
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

6.  Trypanosoma cruzi: differentiation after interaction of epimastigotes and Triatoma infestans intestinal homogenate.

Authors:  E L Isola; E M Lammel; S M González Cappa
Journal:  Exp Parasitol       Date:  1986-12       Impact factor: 2.011

7.  Ribosomal antibody response in rabbits and mice infected with Trypanosoma cruzi.

Authors:  C Sosa Miatello; E R Fiorotto
Journal:  Rev Argent Microbiol       Date:  1989 Jul-Dec       Impact factor: 1.852

8.  The Trypanosoma cruzi ribosomal P protein family: classification and antigenicity.

Authors:  M J Levin; M Vazquez; D Kaplan; A G Schijman
Journal:  Parasitol Today       Date:  1993-10

9.  Antibody response and antigen recognition in human infection with Trypanosoma cruzi.

Authors:  D M Israelski; R Sadler; F G Araujo
Journal:  Am J Trop Med Hyg       Date:  1988-11       Impact factor: 2.345

10.  Chagas' disease: humoral response to subcellular fraction of Trypanosoma cruzi in symptomatic and asymptomatic patients.

Authors:  E H de Titto; M Moreno; M Braun; E L Segura
Journal:  Trop Med Parasitol       Date:  1987-09
View more
  10 in total

1.  Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera.

Authors:  M C Thomas; M V Longobardo; E Carmelo; C Marañón; L Planelles; M E Patarroyo; C Alonso; M C López
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Development and comparison of enzyme immunoassays for diagnosis of Chagas' disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays.

Authors:  Mariolga Berrizbietia; Momar Ndao; Marcelo Gottschalk; Alberto Aché; Fabio Vásquez; Sonia Lacouture; Mehudy Medina; Brian J Ward
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Use of full-length recombinant calflagin and its c fragment for improvement of diagnosis of Trypanosoma cruzi infection.

Authors:  Iván S Marcipar; Cintia Roodveldt; Gerardo Corradi; María L Cabeza; Maria Edileuza F Brito; Lucile M Floeter Winter; Alberto J Marcipar; Ariel M Silber
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection.

Authors:  Sebastián Aguirre; Ariel M Silber; Maria Edileuza F Brito; María E Ribone; Claudia M Lagier; Iván S Marcipar
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

5.  Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease.

Authors:  E S Umezawa; M S Nascimento; N Kesper; J R Coura; J Borges-Pereira; A C Junqueira; M E Camargo
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  Detection and characterization of antigens in urine of patients with acute, congenital, and chronic Chagas' disease.

Authors:  R S Corral; J Altcheh; S R Alexandre; S Grinstein; H Freilij; A M Katzin
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

7.  Evaluation of three commercial enzyme-linked immunosorbent assays for diagnosis of Chagas' disease.

Authors:  W M Oelemann; M D Teixeira; G C Veríssimo Da Costa; J Borges-Pereira; J A De Castro; J R Coura; J M Peralta
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 8.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

Authors:  Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga
Journal:  BMC Infect Dis       Date:  2010-11-25       Impact factor: 3.090

9.  Characterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients.

Authors:  Ivonne D Flechas; Adriana Cuellar; Zulma M Cucunubá; Fernando Rosas; Víctor Velasco; Mario Steindel; María del Carmen Thomas; Manuel Carlos López; John Mario González; Concepción Judith Puerta
Journal:  BMC Infect Dis       Date:  2009-11-25       Impact factor: 3.090

10.  Evolution of anti-Trypanosoma cruzi antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity.

Authors:  Ingebourg Georg; Alejandro Marcel Hasslocher-Moreno; Sergio Salles Xavier; Marcelo Teixeira de Holanda; Eric Henrique Roma; Maria da Gloria Bonecini-Almeida
Journal:  PLoS Negl Trop Dis       Date:  2017-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.